MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.17248

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2022

Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.

Straatmijer Tessa, van Schaik Fiona D M, Bodelier Alexander G L, Visschedijk Marijn, de Vries Annemarie C, Ponsioen Cyriel Y, Pierik Marieke, van Bodegraven Ad A, West Rachel L, de Boer Nanne K H, Srivastava Nidhi, Romkens Tessa E H, Hoekstra Jildou, Oldenburg Bas, Dijkstra Gerard, van der Woude Janneke C, Löwenberg Mark, Mujagic Zlatan, Biemans Vince B C, van der Meulen-de Jong Andrea E, Duijvestein Marjolijn

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment.

AIM: The aim of this study was to assess the effectiveness and safety of 24 months of tofacitinib use in UC patients in the Netherlands.

METHODS

Patients initiating tofacitinib treatment were included in the ICC Registry, a nationwide, observational registry. Patients were prospectively evaluated for up to 24 months. The primary outcome was corticosteroid-free clinical remission (CSFR, Simple Clinical Colitis Activity Index [SCCAI] ≤2) at week 104. Secondary outcomes included biochemical remission (C-reactive protein (CRP) ≤5 mg/L and faecal calprotectin (FC) ≤250 μg/g), safety, and discontinuation rate.

RESULTS

We included 110 patients of whom 104 (94.5%) were anti-TNF experienced. After 104 weeks of tofacitinib, 31.8% (34/107) were in CSFR, 23.4% (25/107) in biochemical remission and 18.7% (20/107) in combined clinical and biochemical remission. Of the patients in CSFR at week 52, 76.5% (26/34) remained so after 104 weeks of treatment. Sixty-one patients (55.5%) discontinued tofacitinib after a median duration of 13 weeks (IQR 7-34). The main reasons for discontinuation were non-response (59%), loss of response (14.8%), and adverse events (18%). There were 33.9 possible tofacitinib-related adverse events per 100 patient-years during follow-up. Adverse events most probably related to tofacitinib were skin reactions and headaches. There were 6.4 herpes zoster infections per 100 patient-years.

CONCLUSION

Tofacitinib was effective in 31.8% of patients after 24 months of treatment.

Для цитирования: Straatmijer Tessa, van Schaik Fiona D M, Bodelier Alexander G L, Visschedijk Marijn, de Vries Annemarie C, Ponsioen Cyriel Y, Pierik Marieke, van Bodegraven Ad A, West Rachel L, de Boer Nanne K H, Srivastava Nidhi, Romkens Tessa E H, Hoekstra Jildou, Oldenburg Bas, Dijkstra Gerard, van der Woude Janneke C, Löwenberg Mark, Mujagic Zlatan, Biemans Vince B C, van der Meulen-de Jong Andrea E, Duijvestein Marjolijn. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.. Alimentary pharmacology & therapeutics. 2022. DOI: 10.1111/apt.17248.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.